Personal Drug Importation Fairness Act of 2017
- Last Action
- 2/10/2017
Actions
- 2017-02-10Referred to the Subcommittee on Health.
- 2017-02-07Referred to the House Committee on Energy and Commerce.
- 2017-02-07Introduced in House
- 2017-02-07Introduced in House
CRS Summary
As of 2017-02-07 (00)
Personal Drug Importation Fairness Act of 2017
This bill allows a drug to be imported by a person other than the drug's manufacturer if the drug: (1) has the same active ingredients, route of administration, and strength as an approved drug; (2) may be lawfully marketed in, and is imported or reimported from, a country included on a list in this Act that the Food and Drug Administration determines has standards for ensuring drug safety and effectiveness that are at least as protective as U.S. standards; (3) is dispensed by a licensed pharmacist; (4) is shipped directly to, or is imported by, the ultimate consumer; (5) is shipped or imported in quantities that do not exceed a 90-day supply; (6) is accompanied by a copy of a valid prescription; and (7) is not a controlled substance.
Cosponsors (1)
- DANA ROHRABACHER (R-CA)
Subjects
- Africa
- Asia
- Australia
- Canada
- Drug safety, medical device, and laboratory regulation
- Europe
- European Union
- Israel
- Japan
- New Zealand
- Oceania
- Prescription drugs
- South Africa
- Switzerland
- Trade restrictions
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.